KalshiCheck availabilityKYC required2% feeVerified resolution dataRoughly calibratedCurrent implied probabilitybefore April 2027 81%Leader of 6 outcomes
Market quality
34 / 100
Low quality24h Volume
$5.7
Liquidity
$3.6K
Medium liquidityBid / Ask
60.0% / 69.0%
Spread
9.0 pt
Wide spreadMarket data
Updated 14 minutes ago
Mar 24, 26, 2:00 PMNov 1, 26, 5:00 AM
Trends
Paper funds only — no real moneyNot financial advice
Selected outcome
before November69%
Volume trend
$6Jul 220d of dataJul 27
Related Markets
Testosterone unscheduled/rescheduled more permissively in US by end of 2028?
$581.6Yes: 17.8%MANIFOLD MARKETS
MANIFOLD MARKETS2026 Ebola epidemic deaths?
$569.1<250: 0.2%MANIFOLD MARKETS
MANIFOLD MARKETSWill there be a cure for schizophrenia before 2032?
$500Yes: 11.8%MANIFOLD MARKETS
MANIFOLD MARKETS
Will there be a year without polio before 2030?
$0Yes: 11%KALSHI
KALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?
$0before September: 15%KALSHI
KALSHI
When will Beam Therapeutics submit a BLA for Risto-cel?
$0before September: 10%KALSHI
KALSHIActive in these topics
Related News
Crypto is the canary in the coal mine for the quantum computing threat, experts sayCoindesk
Galaxy Digital opens $5M fund for Bitcoin quantum security researchCrypto News
Claude's Fable 5 just solved an 87-year-old math problem, and it matters for bitcoinCoindesk
Google DeepMind, Isomorphic Labs Unveil AI-Powered Bioresilience PlanBlockchain.News
NVIDIA's Ising Decoder Slashes Color Code Errors 300xBlockchain.News
NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.NewsRules
If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.